Viemed Healthcare, Inc.

NasdaqCM:VMD Stock Report

Market Cap: US$344.6m

Viemed Healthcare Valuation

Is VMD undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of VMD when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: VMD ($8.85) is trading above our estimate of fair value ($1.54)

Significantly Below Fair Value: VMD is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for VMD?

Key metric: As VMD is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for VMD. This is calculated by dividing VMD's market cap by their current earnings.
What is VMD's PE Ratio?
PE Ratio33.1x
EarningsUS$10.43m
Market CapUS$344.59m

Price to Earnings Ratio vs Peers

How does VMD's PE Ratio compare to its peers?

The above table shows the PE ratio for VMD vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average57.2x
DCGO DocGo
13.5x-50.7%US$417.4m
NRC National Research
16.6xn/aUS$449.3m
AONC American Oncology Network
74.6xn/aUS$173.8m
INFU InfuSystem Holdings
124.1x66.5%US$184.1m
VMD Viemed Healthcare
33.1x32.5%US$344.6m

Price-To-Earnings vs Peers: VMD is good value based on its Price-To-Earnings Ratio (33.1x) compared to the peer average (57.2x).

Price to Earnings Ratio vs Industry

How does VMD's PE Ratio compare vs other companies in the US Healthcare Industry?

3 CompaniesPrice / EarningsEstimated GrowthMarket Cap
NEUE NeueHealth
1.5xn/aUS$41.24m
IDXG Interpace Biosciences
2.6xn/aUS$12.54m
FZMD Fuse Medical
1.1xn/aUS$4.22m
No more companies available in this PE range
VMD 33.1xIndustry Avg. 25.1xNo. of Companies12PE01632486480+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: VMD is expensive based on its Price-To-Earnings Ratio (33.1x) compared to the US Healthcare industry average (25.1x).

Price to Earnings Ratio vs Fair Ratio

What is VMD's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

VMD PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio33.1x
Fair PE Ratio31.4x

Price-To-Earnings vs Fair Ratio: VMD is expensive based on its Price-To-Earnings Ratio (33.1x) compared to the estimated Fair Price-To-Earnings Ratio (31.4x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst VMD forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$8.85
US$12.83
+45.0%
12.9%US$15.00US$11.00n/a3
Nov ’25US$8.61
US$12.27
+42.5%
19.0%US$15.00US$9.30n/a3
Oct ’25US$7.43
US$12.27
+65.1%
19.0%US$15.00US$9.30n/a3
Sep ’25US$7.60
US$11.89
+56.4%
17.9%US$15.00US$9.30n/a4
Aug ’25US$6.86
US$12.75
+85.9%
13.7%US$15.00US$10.76n/a3
Jul ’25US$6.40
US$12.75
+99.2%
13.7%US$15.00US$10.76n/a3
Jun ’25US$7.41
US$12.75
+72.1%
13.7%US$15.00US$10.76n/a3
May ’25US$8.35
US$13.84
+65.7%
15.9%US$15.75US$10.76n/a3
Apr ’25US$9.38
US$13.84
+47.5%
15.9%US$15.75US$10.76n/a3
May ’24US$10.77
US$12.50
+16.1%
20.0%US$15.00US$10.00US$8.352
Apr ’24US$9.66
US$12.50
+29.4%
20.0%US$15.00US$10.00US$9.382
Mar ’24US$9.06
US$13.00
+43.5%
15.4%US$15.00US$11.00US$8.572
Feb ’24US$8.71
US$13.00
+49.3%
15.4%US$15.00US$11.00US$8.262
Jan ’24US$7.56
US$13.00
+72.0%
15.4%US$15.00US$11.00US$7.852
Dec ’23US$7.38
US$13.00
+76.2%
15.4%US$15.00US$11.00US$7.662
Nov ’23US$6.67
US$13.00
+94.9%
15.4%US$15.00US$11.00US$6.072

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

Lantheus Holdings

US$5.3b

Develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide.

LNTH

US$76.83

7D

-12.2%

1Y

12.7%

Patterson Companies

US$1.7b

Engages in the distribution of dental and animal health products in the United States, the United Kingdom, and Canada.

PDCO

US$19.75

7D

-5.0%

1Y

-38.3%

Enhabit

US$369.6m

Provides home health and hospice services in the United States.

EHAB

US$7.35

7D

-6.8%

1Y

-25.2%